yeah agree Slogger - very unlikely in my opinion. Lilly could...

yeah agree Slogger - very unlikely in my opinion. Lilly could have taken ACR out way back when it got its initial FDA approval or even before if it wanted to own the IP.

To buy ACR on market it would likely have to pay a control premium well over and above where it is trading now. The pricing range over the last 12mths would suggest that something >$2 would be needed to be compelling... but at the end of the day - as you say why would Lilly bother - FDA overhang + its not big $$ for them in the scheme of things...

Also ACR has issues with its patients being challenged by the generics - as i understand they are still being challenged through the court system... no news of that yet?

Another issue outstanding for this firm...